According to researchers at Brigham and Women’s Hospital in Boston Ma., men with aggressive prostate cancer who have radiation therapy to treat the cancer have better overall survival rates when the therapy is given at a high volume treatment facility. Paul Nguyen, MD, a physician researcher in the department of Radiation Oncology at Brigham said, “Our paper shows that [...]
Finally, advanced prostate cancer makes it into the genomeic world of cancer. Researchers at the Fred Hutchinson Cancer Research Center and the University of Washington in Seattle published in this week's online edition of the Proceedings of the National Academy of Sciences an announcement that they have mapped the genomes of three different types of [...]
It is estimated that in the United States 200,000 men will be diagnosed with prostate cancer each year with approximately 20% to 30% having clinically aggressive prostate cancer. When diagnosed the standard is to consider factors such as Gleason score and tumor stage to assess a man’s prognosis, however there are no biomarkers to identify [...]
When diagnosed I was told that I had a Gleason score of 7, calculated by adding the first number, a descriptor of the most prevalent cancer cells in the biopsy sample, to the second number, a descriptor for the second most prevalent cancer cells. In my case the actual Gleason score was 4+3 or a [...]
The May 5 issue of the Annals of Internal Medicine carried a report about some recent research looking to identify biomarkers for aggressive prostate cancer. We have been plagued with our inability to differentiate between which prostate cancers are aggressive and will kill and which are actually indolent and will not affect a man’s life. [...]
The American Association of Cancer Researchers (AACR) is in the midst of its annual scientific research meeting in Denver Colorado. As interesting prostate cancer specific information becomes available I will try and share the news. One of the biggest concerns we face in prostate cancer is in deciding when a cancer needs to be treated. [...]
CAUTION, some doctors use estrogen patches as a form of first line hormone blockade therapy for the treatment of prostate cancer. However, scientists from Weill Cornell Medical College, New York City have described the hormone estrogen as a potential key negative player in about half of all prostate cancers. Researchers have found that Estrogen-linked signaling [...]
